BYLOK Trademark
BYLOK is a USPTO trademark filed by Lonza Ltd.. Status: Registered.
Trademark Facts
| Mark | BYLOK |
|---|---|
| Serial Number | 79339202 |
| Registration Number | 6938347 |
| Status | Registered |
| Filing Date | 2022-02-01 |
| Registration Date | 2023-01-03 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Lonza Ltd. |
| Attorney of Record | LAWRENCE J CRAIN |
| Prosecution Events | 25 |
| Latest Event | ARAA on 2024-09-12 |
Goods & Services
Biochemicals, namely, monoclonal and trimeric antibodies and derivatives thereof for in-vivo or in-vitro scientific research and development to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases and for use in laboratories, diagnostics and analytics for scientific or research use | Pharmaceutical preparations based on human monoclonal or trimeric antibodies and derivatives thereof for treating cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, for use in related diagnostic or therapeutic use, and for use as medical diagnostic assays for testing of body fluids or tissues, for use in disease detection, including, cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases | Downloadable computer software for scientific laboratory research and commercial use for applications with monoclonal or trimeric antibodies used to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, namely, software for an algorithm to generate antibody sequences | Medical and scientific research in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; medical research services, namely, protein engineering in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; pharmaceutical product development in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; industrial research in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; and contract research services in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; computer programming for acquisition and processing of medical data in the context of medical-scientific research, development and therapy with monoclonal or trimeric antibodies and their derivatives | Legal services in the field of patent exploitation, namely, patent licensing; licensing of intellectual property in the field of monoclonal and trimeric antibodies for laboratories, diagnostics and analytics for scientific or research use